limited or no options.
Research and Development
At Jazz, we use patient-centric innovation to drive our research and development (R&D) strategy, investment and growth. This starts with identifying unmet needs across our therapeutic areas of focus—neuroscience and oncology—and take the best discovery and development approach to solutions, whether that leverages our proprietary, industry-defining research platforms or our collaborations with leading investigators and bioscience companies.
We believe all people, including those who live with complex conditions, deserve new and better therapeutic options. Our teams use their expertise to lead clinical programs across sleep, epilepsy, movement disorders, psychiatry and neurodegenerative diseases, as well as blood and solid tumor cancers. We are committed to innovation, leveraging both our market-defining cannabinoid science capabilities and other proprietary platforms. As part of our commitment to patients with unmet needs, we continually work to expand the science behind our therapies, acquire rights to develop new medicines, and partner with researchers, academia and other industry leaders to advance molecules with great potential to create new or better standards of care.
(Long-acting Erwinia asparaginase)1
(NRAS and 3 others)1
- R/R AML or HMA Failure MDS2
- First-line, fit AML (Phase 1b)
- Low Intensity Therapy for first-line, unfit AML (Phase 1b)
- HR-MDS (EMSCO)4
- Newly diagnosed older adults with HR-AML3,4
- AML or HR-MDS >60 yrs (AML18)4
- AML or HR-MDS >18 yrs (AML19)4
- Newly diagnosed adults with standard- and HR-AML (AMLSG)4
- Newly diagnosed <22 yrs with AML (COG)4
Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.